BTIG Starts Agios Pharma (AGIO) at Neutral

August 19, 2016 8:33 AM EDT
Get Alerts AGIO Hot Sheet
Price: $40.68 -0.8%

Rating Summary:
    9 Buy, 6 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade AGIO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BTIG initiated coverage on Agios Pharma (NASDAQ: AGIO) with a Neutral rating.

Analyst Ling Wang said, "We are initiating coverage of Agios Pharmaceutical (AGIO) with a Neutral rating. AGIO’s lead oncology assets, AG-221 and AG-120, have shown preliminary anti-tumor activities in AML. We view the market opportunity in AML as limited and the outcome of pivotal Phase III trials in R/R AML hard to handicap. The company’s rare genetic disease (RGD) program will probably become the key value driver, but we would await more definitive efficacy signals to become more bullish."

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $40.55 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities


Add Your Comment